HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S.